Patients with coronary heart disease have, de facto, a high cardiovascular disease risk, making their individual risk calculation unnecessary before starting statin therapy. [2] [3] [4] [5] The key question is not whether a statin should be started in these patients, but rather how aggressive the treatment should be. Although acute coronary syndrome might justify a high dose of statin, 4,5 the risk/benefit of such aggressive approach remains an open question in patients with stable coronary heart disease. 6 The TNT findings suggest that the presence of metabolic syndrome might help to select patients who will best benefit from an aggressive lipid-lowering therapy. In the CASS registry in North America, metabolic syndrome also conferred a higher risk of long-term death in patients with pre-existing coronary heart disease, and dysglycaemia seemed to be responsible for most of the associated risk.
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In TNT, univariate analysis of the individual characteristics of metabolic syndrome showed a significant, and almost similar, increased risk of major cardiovascular events with the presence of each component of metabolic syndrome. Interestingly, the risk of major cardiovascular events increased with the presence of each additional component of metabolic syndrome.
In patients without cardiovascular disease, the decision about starting a statin relies on the calculation of a global cardiovascular disease risk, taking into account many classic risk factors, but not some others that form part of the metabolic syndrome. [2] [3] [4] However, in the INTERHEART study, abdominal obesity, a key feature of metabolic syndrome, accounted for 44% of the risk of a first myocardial infarction. 12 Unfortunately, because waist circumference was not measured in TNT, the two most popular definitions of metabolic syndrome (National Cholesterol Education Program, International Diabetes Federation) could not be used in their strict sense for the analysis. More importantly, the value of metabolic syndrome compared with the Framingham equation for individual risk stratification has been challenged in primary prevention. 13 In the San Antonio Heart Study, metabolic syndrome predicts less effectively the future development of cardiovascular disease than the established Framingham risk score, and does not enhance the performance of the Framingham score when combined with it. 14 The results from TNT lend further support to implementing lower lipid goals than those currently suggested by guidelines. However, when treatment with high statin doses is considered, the selection of patients whose risk of major cardiovascular events is high enough to outweigh the potential risk of toxic drug-related effects is most important. The two post-hoc analyses of TNT in patients with diabetes and/or metabolic syndrome support the concept of the higher the risk, the greater the need to treat and to treat aggressively. This concept, already accepted in primary prevention, might be extended to secondary prevention, although such a suggestion requires further assessment. 
